Enhanced Dermatologic Care Reduced AEs from MARIPOSA Regimen in NSCLC

by

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Interim results from the phase 2 COCOON trial (NCT06120140) showed that the primary end point of a reduction in the frequency of moderate-to-severe skin and nail adverse effects (AEs) and skin-related AEs compared with a standard dermatologic regimen in patients with newly diagnosed or locally advanced non–small cell lung cancer (NSCLC) who received first-line treatment with amivantamab-vmjw (Rybrevant) and lazertinib (Lazcluze), a press release from the developer, Johnson & Johnson, stated.1

Arm A consisted of amivantamab and Lazertinib plus standard dermatologic managementand either 100 mg of doxycycline or minocycline administered orally twice daily for up to 12 weeks;…

Source link

Related posts:

  1. Polyphenols: the natural chemicals that could give you a small waist, healthy heart and low blood pressure – The Guardian
  2. Skeletal Muscle Function in Relation to COPD Severity and Its Predicti
  3. Addressing Dementia in refugees and migrants- Epidemiology, public health implications and global responses
  4. Effects of preoperative magnesium sulphate infusion on emergence agita

Leave a Comment